David Malebranche, M.D., M.P.H.
David Malebranche, M.D., M.P.H., is a black same-gender-loving educator, author, activist, and internal medicine physician. He co-hosts the YouTube series 'Revolutionary Health' as part of The Counter Narrative Project and also appears on the #AskTheHIVDoc video series.
Latest by David Malebranche, M.D., M.P.H.
Our updated medical advice from HIV doctors and health experts on how to remain healthy during the COVID-19 pandemic if you're living with HIV in the U.S., including guidance on vaccines.
Viread (a.k.a. TDF or tenofovir disoproxil fumarate) turns 20 this year, but it's still a very common medication taken by people living with HIV or as PrEP.
From dosing to side effects to drug interactions and everything in between, here's all the basics on the first-ever injectable treatment regimen for HIV.
The integrase inhibitor Tivicay is a critical component of some of the most commonly used HIV treatment regimens in the U.S. today.
An old HIV medication that's still a part of many people's treatment regimens, there's plenty to know about what makes this “booster” drug tick—and why it has such a long-lived history.
Deeeply researched and medically reviewed, our "no-BS basics" on Odefsey will get you in the know about the most important info regarding this single-tablet HIV treatment regimen.
It's the oldest single-tablet regimen for HIV. But is it washed up as a viable treatment option? Here's a top expert's take.
It’s not considered a “preferred” option for starting HIV treatment in the U.S., but Genvoya still has its place in our medication arsenal.
What makes this two-drug regimen for HIV so unique? An expert HIV clinician walks us through the details.
The basics on the first HIV integrase inhibitor, including recommended dosing, what its potential side effects are, and how it stacks up against more recently approved drugs in its class.